Pfizer Inc. confirmed the received marketing approval by the EC for LITFULO™ (ritlecitinib)  aimed for the treatment of severe alopecia areata in adults and adolescents aged 12 years and above.

Heidelberg Pharma AG announced it began patient recruitment for the fifth group in the Phase I/IIa trial of their main development candidate, HDP-101, with a dose of 100 µg/kg.

Orexo AB recently submitted its NDA to the US FDA for OX124, a high-dose, nasally-administered treatment for opioid overdoses.

Kite's Car T-cell Therapy Yescarta® exhibits a substantial treatment response rate and durable remission for patients with relapsed/resistant Large B-cell Lymphoma.

Vividion Therapeutics, Inc., confirmed the commencement of patient dosing for a Phase I cancer clinical trial concerning its experimental oral agent, KEAP1 activator VVD-130037.

NeuroBo Pharmaceuticals, Inc. has started its Phase 2a clinical trial using DA-1241, a unique GPR119 agonist, to treat the first patient with nonalcoholic steatohepatitis.

GSK plc has confirmed that Ojjaara(momelotinib), a daily oral JAK1/JAK2 and activin A receptor type 1 inhibitor, has received approval from the US FDA.

Harpoon Therapeutics announced that AbbVie has offered a unique licensing opportunity for its HPN217 program, targeting BCMA, as per their Development and Option Agreement.

Vincerx Pharma, Inc. declared that the initial patient in the Phase 1 clinical trial has received treatment with VIP943.

Oscotec Inc. and ADEL Inc. has announced that the FDA has given the IND application approval for ADEL-Y01 to be used in the treatment of Alzheimer's Disease.

Nektar Therapeutics disclosed fresh clinical results concerning rezpegaldesleukin utilised for patients battling atopic dermatitis, featuring new clinical effectiveness parameters from its Phase 1b research.

Coeptis Therapeutics delivers an update on the safety and dosage from Phase 1 Trials of DVX201, intended for those with Relapsed/Refractory AML or High Risk MDS.